Morgan Guénolé1, Paolo Bénigni2, Vincent Bourbonne1,3, François Lucia4,5, Delphine Legoupil6,7, Olivier Pradier1,3, Laurent Misery6,7, Arnaud Uguen2, Ulrike Schick1,3. 1. Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, Brest, France. 2. Department of Dermatology, University Hospital Morvan, Brest, France. 3. Latim INSERM UMR 1101, UBO, Brest, France. 4. Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, Brest, France. francois.lucia@chu-brest.fr. 5. Latim INSERM UMR 1101, UBO, Brest, France. francois.lucia@chu-brest.fr. 6. Department of Pathology, University Hospital Morvan, Brest, France. 7. LIEN, UBO, Brest, France.
Abstract
INTRODUCTION: The aim of this study was to evaluate prognostic factors in patients with non-metastatic Merkel cell carcinoma (MCC), with a particular focus on immunological markers such as TILs subtyping (CD3, CD8, CD68, FoxP3, PD-L1 and PD-1) and MCPyV. METHODS: Patients treated for a non-metastatic MCC with oncologic surgical resection followed or not by adjuvant radiotherapy between 01/2007 and 12/2018 were analyzed. Local and regional control (LC, RC), distant metastasis-free survival (DMFS) and overall survival (OS) were evaluated. Clinical variables analyzed included age, gender, performance status, comorbidity, tumor size, location and presentation type, extension, oncologic resection and adjuvant radiotherapy. Pathological variables analyzed included type of tumor-infiltrating lymphocytes, CD3, CD8, CD68, PD-L1 expression on immune cells and tumors cells, PD-1, FoxP3 and MCPyV, assessed with immunohistochemistry (IHC). RESULTS: 77 patients were included. After a median follow-up of 18 months (range 0.2-144), the 1-year LC, RC, DMFS and OS were 83%, 60%, 82% and 75%, respectively. In multivariate analysis, a percentage of PD-L1 expression by immune cells ≥ 1% was significantly correlated with improvement of RC (p = 0.012), DMFS (p = 0.003) and OS (p = 0.006). Adjuvant radiotherapy significantly improved DMFS (p = 0.021) and OS (0.041) rates. There was a correlation between the presence of MCPyV + and the expression of PD-L1 on IC (p = 0.05) and TC (p = 0.03). CONCLUSION: PD-L1 expression by immune and tumor cells in non-metastatic MCC seems to significantly improve outcome in patients who did not received PD-1/PD-L1 inhibitors. Prospective studies are needed to confirm our hypothesis.
INTRODUCTION: The aim of this study was to evaluate prognostic factors in patients with non-metastatic Merkel cell carcinoma (MCC), with a particular focus on immunological markers such as TILs subtyping (CD3, CD8, CD68, FoxP3, PD-L1 and PD-1) and MCPyV. METHODS:Patients treated for a non-metastatic MCC with oncologic surgical resection followed or not by adjuvant radiotherapy between 01/2007 and 12/2018 were analyzed. Local and regional control (LC, RC), distant metastasis-free survival (DMFS) and overall survival (OS) were evaluated. Clinical variables analyzed included age, gender, performance status, comorbidity, tumor size, location and presentation type, extension, oncologic resection and adjuvant radiotherapy. Pathological variables analyzed included type of tumor-infiltrating lymphocytes, CD3, CD8, CD68, PD-L1 expression on immune cells and tumors cells, PD-1, FoxP3 and MCPyV, assessed with immunohistochemistry (IHC). RESULTS: 77 patients were included. After a median follow-up of 18 months (range 0.2-144), the 1-year LC, RC, DMFS and OS were 83%, 60%, 82% and 75%, respectively. In multivariate analysis, a percentage of PD-L1 expression by immune cells ≥ 1% was significantly correlated with improvement of RC (p = 0.012), DMFS (p = 0.003) and OS (p = 0.006). Adjuvant radiotherapy significantly improved DMFS (p = 0.021) and OS (0.041) rates. There was a correlation between the presence of MCPyV + and the expression of PD-L1 on IC (p = 0.05) and TC (p = 0.03). CONCLUSION:PD-L1 expression by immune and tumor cells in non-metastatic MCC seems to significantly improve outcome in patients who did not received PD-1/PD-L1 inhibitors. Prospective studies are needed to confirm our hypothesis.
Authors: Christopher K Bichakjian; Lori Lowe; Christopher D Lao; Howard M Sandler; Carol R Bradford; Timothy M Johnson; Sandra L Wong Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: Laurence Feldmeyer; Courtney W Hudgens; Genevieve Ray-Lyons; Priyadharsini Nagarajan; Phyu P Aung; Jonathan L Curry; Carlos A Torres-Cabala; Barbara Mino; Jaime Rodriguez-Canales; Alexandre Reuben; Pei-Ling Chen; Jennifer S Ko; Steven D Billings; Roland L Bassett; Ignacio I Wistuba; Zachary A Cooper; Victor G Prieto; Jennifer A Wargo; Michael T Tetzlaff Journal: Clin Cancer Res Date: 2016-05-10 Impact factor: 12.531
Authors: Franchesca D Choi; Christina N Kraus; Ashley N Elsensohn; Sama K Carley; Larisa M Lehmer; Rebecca T Nguyen; Kenneth G Linden; Jessica Shiu Journal: J Am Acad Dermatol Date: 2019-06-01 Impact factor: 11.527
Authors: Timothy L Fitzgerald; Samuel Dennis; Swapnil D Kachare; Nasreen A Vohra; Jan H Wong; Emmanuel E Zervos Journal: Am Surg Date: 2015-08 Impact factor: 0.688